

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 64803

**Title:** Treatment for atypical  $\gamma\delta$  T-cell large granular lymphocytic leukemia with pure red cell aplasia: A case report

**Reviewer's code:** 05224683

**Position:** Peer Reviewer

**Academic degree:** DSc, MSc

**Professional title:** Postdoc, Postdoctoral Fellow, Research Scientist, Senior Scientist

**Reviewer's Country/Territory:** Bangladesh

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-23

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2021-05-23 12:39

**Reviewer performed review:** 2021-05-23 13:01

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

#### **SPECIFIC COMMENTS TO AUTHORS**

This case report is important to understand about the treatment of rare  $\gamma\delta$  T-LGLL with pure red cell aplasia (PRCA). I am interested to know which gene/s are likely involved for this disease. There are few reports suggested that STAT3, STAT5b, AIRE genes when mutated, then directly linked with  $\gamma\delta$  T-LGLL with pure red cell aplasia (PRCA) disease. So, if possible, research team can identify the molecular mechanism of the disease by whole genome sequencing.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 64803

**Title:** Treatment for atypical  $\gamma\delta$  T-cell large granular lymphocytic leukemia with pure red cell aplasia: A case report

**Reviewer's code:** 04107278

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Senior Scientist

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-23

**Reviewer chosen by:** Jia-Ping Yan

**Reviewer accepted review:** 2021-05-26 12:41

**Reviewer performed review:** 2021-05-26 13:36

**Review time:** 1 Hour

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input checked="" type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## **SPECIFIC COMMENTS TO AUTHORS**

1. Title should include treatment option not just a case report. 2. Please write full forms in abstract 3. There is discrepancy in rise in hemoglobin, in abstract it is 110, while in core tip it is 100. 4. In abstract should include treatment with erythropoietin. 5. In treatment section, it is not clear whether erythropoietin is stopped or continued. 6. In treatment section, authors have mentioned that HGB increased after 3 months, but in abstract it is 2 months. 7. It is reported that  $\gamma\delta$  variant is very similar  $\alpha\beta$  (J Hematop. 2008 Sep; 1(2): 139-143). Then, what is the novelty in treating patients with cyclophosphamide with case mentioned in manuscript. 8. Please discuss in detail about the use of prednisolone and methotrexate can increase in hemoglobin in these patients in discussion section. 9. Methotrexate can cause bone marrow suppression; it cannot increase hemoglobin. Please discuss how it could increase hemoglobin levels. 10. How cyclophosphamide could have increased hemoglobin in the patient. Describe it mechanistically. 11. As mentioned in ref 10, that CTX has highest response. Then what is the novel finding from this case. 12. Conclusion should be related to case reports. It should highlight the results from case report. 13. In manuscript, missing space between words, 14. Figure 2 should be provided with 1000 X magnification, as used in figure 1.

## RE-REVIEW REPORT OF REVISED MANUSCRIPT

**Name of journal:** World Journal of Clinical Cases

**Manuscript NO:** 64803

**Title:** Treatment for atypical  $\gamma\delta$  T-cell large granular lymphocytic leukemia with pure red cell aplasia: A case report

**Reviewer's code:** 04107278

**Position:** Peer Reviewer

**Academic degree:** PhD

**Professional title:** Senior Scientist

**Reviewer's Country/Territory:** India

**Author's Country/Territory:** China

**Manuscript submission date:** 2021-02-23

**Reviewer chosen by:** Jia-Ru Fan

**Reviewer accepted review:** 2021-07-05 03:24

**Reviewer performed review:** 2021-07-05 06:27

**Review time:** 3 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Peer-reviewer statements</b>	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
<https://www.wjgnet.com>

Authors discussed that the case report is of CD57 negative. I think adding CD57 negative in title can increase the specificity and novelty of the paper. There is a mistake in OUTCOME and FOLLOWUP. authors have wrote, 5 mo, please correct it to 5 month. Authors should remove first sentence of the conclusion. conclusion should not have background information. Still manuscript need language correction. These are many sentences which needs correction.